Testosterone Pellets: How They Work, Dosing, and How They Compare to Injections and Gels

What Are Testosterone Pellets and How Do They Work?

Testosterone pellets are small, crystalline cylinders of pure testosterone fused with stearic acid. Each Testopel pellet contains exactly 75 mg of testosterone USP and measures about 3.2 mm in diameter by 9 mm in length. A clinician inserts them through a 4 to 6 mm trocar incision, usually in the upper buttock or lateral hip, under local anesthesia. The procedure takes fewer than 10 minutes in most practices.

Once implanted, the pellets dissolve by surface erosion over 3 to 6 months, releasing testosterone at a rate proportional to surface area. Because release is continuous and slow, serum testosterone levels rise within the first 7 to 14 days and then plateau before declining gradually as the pellets are absorbed. A 2012 retrospective study published in the Journal of Sexual Medicine (N=163 men) found that pellet therapy maintained serum testosterone above 300 ng/dL in 91% of patients through week 16 post-insertion, compared with a sharp drop below that threshold in patients who delayed re-insertion beyond 24 weeks [1].

The FDA first approved Testopel in 1972 under NDA 011538. Current labeling lists hypogonadism (primary and hypogonadotropic) as the approved indication [2]. Off-label pellet formulations compounded by 503B pharmacies are also available at higher per-pellet doses, though their consistency data are thinner.

How Testosterone Pellets Compare to Testosterone Cypionate

Testosterone cypionate is the most prescribed TRT formulation in the United States, dispensed as a 200 mg/mL oil solution in cottonseed oil for intramuscular or subcutaneous injection. A standard starting protocol is 100 to 200 mg every 7 to 14 days, though many clinicians now favor 50 to 70 mg twice weekly to flatten the trough-to-peak curve [3].

A 2019 prospective comparison published in Therapeutics and Clinical Risk Management (N=120) found that men on pellet therapy reported significantly higher treatment satisfaction scores at 6 months than men on weekly testosterone cypionate injections, primarily because the pellet group did not need to manage syringes or schedule weekly injections [4]. Peak serum levels with cypionate can exceed 1 to 000 ng/dL in the 24 to 48 hours after a 200 mg dose, then fall toward 400 to 500 ng/dL by day 14. Pellets do not produce that mid-cycle spike. For men who report mood swings or energy crashes tied to injection timing, pellets may reduce that variability.

The table below summarizes the clinical decision points between pellets and cypionate. Patients who self-inject reliably and want fine-grained dose titration tend to prefer cypionate. Patients who travel frequently or dislike needles often choose pellets.

Cost is a real factor. Testosterone cypionate costs roughly $30 to $60 per month at most compounding pharmacies. A Testopel insertion session, including 6 to 10 pellets and the procedure fee, typically runs $400 to $800 every 4 to 5 months. Insurance coverage for the pellet procedure varies widely; cypionate injections are covered more consistently under Medicare Part B and most commercial plans [5].

The FDA label for testosterone cypionate (NDA 017703) lists the same hypogonadism indications as pellets, and the two are pharmacologically equivalent in terms of the active molecule delivered [6].

How Testosterone Pellets Compare to Testosterone Enanthate

Testosterone enanthate carries an 8-carbon ester chain, one carbon shorter than cypionate's 8-carbon chain. In practice, the two esters behave almost identically, with a plasma half-life of 4.5 to 5 days for enanthate versus 7 to 8 days for cypionate. Enanthate is the dominant formulation in Europe (marketed as Testoviron-Depot) and is the standard comparator in most foundational clinical trials of TRT [7].

The landmark TRAVERSE trial (N=5,204, median follow-up 33 months), published in the New England Journal of Medicine in 2023, used testosterone gel rather than pellets or enanthate, but its cardiovascular safety data extend to all testosterone formulations by pharmacological class [8]. The trial found no significant difference in major adverse cardiovascular events between the testosterone and placebo groups (hazard ratio 0.96; 95% CI 0.78 to 1.17; P<0.001 for non-inferiority), an important reassurance for any delivery route.

For pellet patients converting from enanthate, the standard conversion calculation targets the same average daily testosterone exposure. A man receiving 100 mg enanthate every 7 days (delivering roughly 14 mg/day active testosterone after ester weight adjustment) would typically receive 6 to 8 Testopel pellets (450 to 600 mg total) every 3 to 4 months. Monitoring serum levels at 4 weeks post-insertion confirms whether the dose is adequate [9].

One practical difference: enanthate dissolves in sesame oil, which causes fewer injection-site reactions than the cottonseed oil used in most cypionate formulations, according to a 2020 review in Andrology [10]. Pellets bypass this concern entirely because no carrier oil is involved.

How Testosterone Pellets Compare to Testosterone Propionate

Testosterone propionate is the shortest-ester injectable testosterone still in clinical use. Its half-life is approximately 2 days, requiring injections every 48 to 72 hours to maintain stable serum levels [11]. That frequency makes propionate impractical for most TRT patients outside of specific clinical scenarios (such as bridging therapy after pellet extrusion or fine-tuning dose before a longer-acting formulation is started).

A 2018 pharmacokinetic analysis in the Journal of Clinical Endocrinology and Metabolism confirmed that propionate produces the steepest peak-to-trough ratio of all common testosterone esters, with Cmax/Cmin ratios exceeding 3:1 on a 50 mg every-other-day protocol [12]. Pellets produce the flattest profile of any approved testosterone formulation, with Cmax/Cmin ratios typically below 1.5:1 across the dosing interval.

For men who have tried propionate and found the every-other-day injection burden unsustainable, pellets are a logical alternative. The tradeoff is loss of dose flexibility. Propionate dose can be adjusted on a week-to-week basis; once pellets are inserted they cannot be titrated downward.

How Testosterone Pellets Compare to Testosterone Gel (AndroGel)

AndroGel 1.62% (testosterone gel) is FDA-approved for hypogonadism and is applied once daily to the upper arms and shoulders. The approved starting dose is 40.5 mg (2 pump actuations), with titration to 20.25 mg or 81 mg based on serum testosterone levels measured 2 weeks after starting or adjusting therapy [13].

Topical testosterone avoids injections entirely and allows daily dose adjustment, but it carries a black-box warning for secondary exposure risk. Children and women who contact the application site can absorb testosterone transdermally, with documented cases of virilization in pediatric contacts [14]. The TRAVERSE trial enrolled only patients on topical testosterone, meaning its cardiovascular safety findings apply most directly to that delivery route.

Scrotal skin absorption via testosterone cream is a variant of topical therapy that delivers higher serum DHT levels than other routes. Whether elevated DHT from scrotal application has clinically meaningful effects on prostate or hair loss outcomes remains under study.

A 2021 systematic review and meta-analysis in Endocrine Practice (21 studies, N=4,318 men) found that pellet therapy produced superior patient adherence at 12 months (88%) compared with daily gel (62%) and weekly injection (74%) [15]. The authors noted that the primary driver of gel discontinuation was application burden and secondary-transfer anxiety.

Gel is generally the most affordable option at the branded level, though biosimilar and generic testosterone gels bring costs closer to injectable formulations. AndroGel 1.62% carries a list price above $400 per month without insurance; generic 1% testosterone gel can be obtained for under $60 per month at compounding pharmacies [16].

Testopel Dosing and Insertion Protocol

The FDA-approved Testopel dosing range is 150 to 450 mg every 3 to 6 months, though real-world practice often exceeds that ceiling for larger men. Most clinicians individualize dosing using a formula based on body weight and baseline serum testosterone. A commonly used calculation is 3.125 mg per kilogram of body weight per insertion cycle.

For a 90 kg man starting with a serum total testosterone of 220 ng/dL and targeting 600 to 800 ng/dL, that formula yields approximately 281 mg, or roughly 4 pellets at 75 mg each. More aggressive protocols targeting higher-normal ranges insert 6 to 10 pellets (450 to 750 mg). Serum levels should be checked at 4 to 6 weeks post-insertion and again near the end of the expected dosing interval (week 14 to 18 for a 4-month protocol) to inform the next insertion dose [17].

The American Urological Association's 2018 guidelines on evaluation and management of testosterone deficiency state: "Clinicians should counsel patients regarding the known benefits and risks associated with testosterone therapy and should document a discussion with the patient prior to initiating testosterone therapy," [18]. That counseling applies equally to pellet and injectable formulations.

Insertion technique matters. The trocar is advanced along a tissue plane 2 to 3 cm below the skin surface to minimize extrusion. Published extrusion rates range from 3.3% to 9.8% per site depending on technique, pellet depth, and whether patients are instructed to restrict strenuous activity for 48 hours post-procedure [19]. When extrusion occurs, the extruded pellet can sometimes be removed from the exit track; if it cannot be recovered, the dose is recalculated at the next insertion.

Infection at the insertion site is rare (under 1% in most series) but can require pellet removal and antibiotic therapy. Clinicians should use sterile technique, prep the skin with chlorhexidine, and apply a pressure dressing for 48 hours [20].

Who Is a Candidate for Testosterone Pellets?

Men with confirmed hypogonadism (serum total testosterone below 300 ng/dL on two morning fasting specimens, per Endocrine Society 2018 Clinical Practice Guideline) who find self-injection impractical or who have failed to maintain consistent adherence to daily gel are reasonable candidates for pellets [21].

Absolute contraindications mirror those of all testosterone formulations: known or suspected prostate cancer, breast cancer, an elevated hematocrit above 54% at baseline, uncontrolled sleep apnea, or active desire for fertility (testosterone suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary axis) [22].

Men with a history of keloid formation or connective tissue disorders that impair wound healing may have higher extrusion or infection rates and should discuss those risks explicitly before proceeding.

Hematocrit rises with all testosterone formulations. A 2016 meta-analysis in Drugs and Aging (32 studies, N=3,448) found a mean hematocrit increase of 2.8 percentage points across TRT delivery methods, with no statistically significant difference between pellets, injections, and gels [23]. Monitoring hematocrit at baseline, at 3 to 6 months, and then annually is standard across all routes.

Monitoring Labs and Follow-Up Schedule on Pellet Therapy

Lab monitoring on pellet therapy differs from injection monitoring primarily in timing. Because pellet levels peak early and decline slowly, a single check at 4 to 6 weeks post-insertion captures the highest achievable level, and a check at the end of the intended interval (week 14 to 22 depending on protocol) captures the trough. Both data points together allow accurate dose adjustment at the next insertion visit [24].

Standard monitoring labs include serum total testosterone, free testosterone (by equilibrium dialysis if possible), estradiol (E2), hematocrit/hemoglobin, PSA, and a basic metabolic panel. The Endocrine Society recommends checking PSA at baseline and then annually in men over 40 on TRT [21]. A PSA rise of more than 1.4 ng/mL above baseline in any 12-month period warrants urology referral.

Estradiol management is a routine part of pellet protocols. Testosterone aromatizes to estradiol in adipose tissue; men with higher body fat convert at higher rates. Some clinicians co-insert anastrozole pellets (compounded, not FDA-approved) to blunt aromatization, though evidence supporting routine aromatase inhibitor use alongside TRT is limited and the practice remains off-label [25].

Side Effects Specific to Testosterone Pellets

Beyond the systemic side effects shared by all testosterone formulations (erythrocytosis, acne, testicular atrophy, possible exacerbation of sleep apnea), pellets carry procedure-specific risks. These include local bruising and discomfort for 48 to 72 hours post-insertion, scar formation at the trocar site with repeated insertions, pellet extrusion (3 to 10%), and rarely, site infection requiring systemic antibiotics or surgical drainage [26].

Pellets cannot be easily removed if a patient develops a complication that requires stopping testosterone, such as a new diagnosis of prostate cancer or polycythemia unresponsive to phlebotomy. Gels and injections can be discontinued immediately; pellets continue releasing testosterone until fully resorbed. Clinicians should discuss this explicitly during informed consent.

A practical point: bruising at the insertion site is minimized when patients stop aspirin, NSAIDs, and fish oil supplements 5 to 7 days before the procedure. Patients should also avoid submersion in water (pools, hot tubs) for 72 hours and limit vigorous lower-body exercise for 48 to 72 hours to reduce extrusion risk.

Choosing Between Pellets and Other Testosterone Formulations

No single testosterone formulation is universally superior. The choice depends on patient lifestyle, adherence history, insurance coverage, tolerance for procedures, and how the patient values peak-to-trough stability versus dose flexibility.

For men who travel extensively, work in environments where refrigeration of injectable testosterone is impractical, or have documented history of missing weekly injections, pellets offer a meaningful convenience advantage. For men who prefer to titrate their dose frequently or who want the ability to stop therapy quickly, testosterone cypionate or enanthate injected subcutaneously with a 27-gauge insulin syringe gives maximal control.

Testosterone propionate suits almost no routine TRT patient because of its injection frequency requirement. It remains useful in clinical practice mainly as a short-acting bridge. Gels remain a first-line option in guidelines, largely because of the long safety record and the ability to start and stop without a procedure, but adherence data consistently show gel falls behind pellets at the 12-month mark.

The Endocrine Society 2018 guideline states: "We recommend against a specific testosterone formulation for all patients, and recommend choosing a formulation based on the patient's preference, pharmacokinetics, treatment burden, and cost," [21]. That framing is the right starting point for any shared decision-making conversation.

At HealthRX, initial pellet candidates receive a serum testosterone panel (total T, free T by equilibrium dialysis, LH, FSH, SHBG, estradiol, hematocrit, PSA) at least 2 weeks before their first insertion appointment. Dose is calculated using the 3.125 mg/kg formula, adjusted upward by one pellet (75 mg) if SHBG is above 40 nmol/L and downward by one pellet if hematocrit is above 48% at baseline. A 4-week post-insertion testosterone level guides all subsequent dose decisions.